Liraglutide vs Tirzepatide
Research Verdict
Neither compound has a universal evidence advantage. Research distinction: Lower-cost alternative when formulary access drives choice, or when a less potent GLP-1 agent with d vs. tirzepatide goals.
Quick Answers
Which is better, Liraglutide or Tirzepatide?
Neither compound has a universal evidence advantage. Research distinction: Lower-cost alternative when formulary access drives choice, or when a less potent GLP-1 agent with d vs. tirzepatide goals.
What is the key difference between Liraglutide and Tirzepatide?
The 14-percentage-point weight loss gap (~8% vs. ~22.5%) is among the largest therapeutic efficacy differences seen between approved agents in the same indication - tirzepatide represents a generational step up in obesity pharmacotherapy.
Evidence Comparison
Both FDA approved; tirzepatide SURMOUNT-1 (22.5% mean weight loss at 15 mg) vastly exceeds liraglutide SCALE (8% at 3.0 mg). Tirzepatide's dual GLP-1/GIP mechanism explains superior efficacy. Tirzepatide approved for T2DM (Mounjaro) and obesity (Zepbound); liraglutide for T2DM (Victoza) and obesity (Saxenda).
Evidence Context Favoring Liraglutide
Lower-cost alternative when formulary access drives choice, or when a less potent GLP-1 agent with daily injection is appropriate for a specific patient profile.
Evidence Context Favoring Tirzepatide
Maximum weight loss efficacy is the goal - tirzepatide's Phase 3 data is unambiguous.
Side-by-Side Snapshot
| Evidence grade | Liraglutide: Level A Tirzepatide: Level A |
|---|---|
| Research status | Liraglutide: FDA Approved Tirzepatide: FDA Approved |
| Primary category | Liraglutide: Weight Loss & Metabolic Tirzepatide: Weight Loss & Metabolic |
| Cited studies | Liraglutide: 2 Tirzepatide: 5 |